Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
St. Jude Medical’s attempts to distance its next-generation Durata defibrillator leads from the high-profile Riata recall may be making inroads with investors, analysts and physicians. Medical device maker St. Jude Medical (NYSE:STJ) is feeling pretty confident about public perception of its Durata defibrillator leads, which came under scrutiny amid a high-profile recall of its older Riata leads. Sentiments during last month’s Heart Rhythm Society meeting were positive, St. Jude corporate relations vice president Rachel Ellingson said during a presentation at the 38th annual Deutsche Bank healthcare conference.
Help employers find you! Check out all the jobs and post your resume.
